Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | $0.53 | $0.55 | $0.54 |
Q2 2025 | 1 | $0.64 | $0.65 | $0.65 |
Q3 2025 | 1 | $0.73 | $0.75 | $0.74 |
Q4 2025 | 1 | $0.75 | $0.76 | $0.75 |
Teva Pharmaceutical Industries Limited last posted its earnings results on Wednesday, November 6th, 2024. The company reported $0.69 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.04. The company had revenue of 4.33 B for the quarter and had revenue of 15.85 B for the year. Teva Pharmaceutical Industries Limited has generated $-1 earnings per share over the last year ($-0.5 diluted earnings per share) and currently has a price-to-earnings ratio of -23.73. Teva Pharmaceutical Industries Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 29th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | $0.65 | -$0.39 | -1.04 | $4.14 B | $4.33 B |
07/31/2024 | Q2 2024 | $0.57 | -$0.75 | -1.32 | $4.06 B | $4.16 B |
05/08/2024 | Q1 2024 | $0.51 | -$0.12 | -0.63 | $3.83 B | |
02/12/2024 | Q4 2023 | $0.41 | $4.46 B | |||
11/09/2023 | Q3 2023 | $0.07 | $3.73 B | $3.85 B | ||
08/02/2023 | Q2 2023 | $0.54 | -$0.77 | -1.31 | $3.71 B | $3.88 B |
05/10/2023 | Q1 2023 | $0.57 | -$0.18 | -0.75 | $3.66 B | |
02/10/2023 | Q4 2022 | -$1.10 | $3.88 B | |||
11/03/2022 | Q3 2022 | $0.61 | $0.05 | -0.56 | $3.84 B | $3.60 B |
07/27/2022 | Q2 2022 | -$0.21 | $3.78 B | $3.79 B | ||
05/03/2022 | Q1 2022 | $0.55 | -$0.86 | -1.41 | $3.66 B | |
02/09/2022 | Q4 2021 | $0.74 | -$0.14 | -0.88 | $4.10 B | |
10/27/2021 | Q3 2021 | $0.65 | $0.26 | -0.39 | $4.03 B | $3.89 B |
07/28/2021 | Q2 2021 | $0.57 | $0.19 | -0.38 | $4.02 B | $3.91 B |
04/28/2021 | Q1 2021 | $0.58 | $0.07 | -0.51 | $3.98 B | |
02/10/2021 | Q4 2020 | $0.62 | $0.14 | -0.48 | $4.45 B | |
11/05/2020 | Q3 2020 | $0.58 | -$3.97 | -4.55 | $4.07 B | $3.98 B |
08/05/2020 | Q2 2020 | $0.51 | $0.13 | -0.38 | $3.93 B | $3.87 B |
05/07/2020 | Q1 2020 | $0.59 | $0.06 | -0.53 | $4.36 B | |
02/21/2020 | Q4 2019 | $0.10 | $4.47 B |
Teva Pharmaceutical Industries Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 29th, 2025 based off last year's report dates.
In the previous quarter, Teva Pharmaceutical Industries Limited (:TEVA) reported $0.69 earnings per share (EPS) to beat the analysts' consensus estimate of $0.65 by $0.04.
The conference call for Teva Pharmaceutical Industries Limited's latest earnings report can be listened to online.
The conference call transcript for Teva Pharmaceutical Industries Limited's latest earnings report can be read online.
Teva Pharmaceutical Industries Limited (:TEVA) has a recorded annual revenue of $15.85 B.
Teva Pharmaceutical Industries Limited (:TEVA) has a recorded net income of $15.85 B. Teva Pharmaceutical Industries Limited has generated $-0.5 earnings per share over the last four quarters.
Teva Pharmaceutical Industries Limited (:TEVA) has a price-to-earnings ratio of -23.73 and price/earnings-to-growth ratio is 0.34.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED